Evidence map›Paper›PMID 35103829›Full record

ArticleEuropean radiology2022

Balancing the benefits and harms of MRI-directed biopsy pathways.

Anwar R Padhani, Masoom A Haider, Olivier Rouviere

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Value for combination of TZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anwar R PadhaniPaul Strickland Scanner Centre, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, HA6 2RN, Middlesex, UK. anwar.padhani@stricklandscanner.org.uk.ORCID http://orcid.org/0000-0002-5830-5777
Masoom A HaiderJoint Department of Medical Imaging, University Health Network, Sinai Health System and University of Toronto, Toronto, ON, Canada.
Olivier RouviereDepartment of Urinary and Vascular Radiology, Hospices Civils de Lyon, Hôpital Édouard-Herriot, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

key points• Before a prostate biopsy, the likely benefits and the harms emanating from true and false test MRI results need to be balanced. Prioritizing patients' preferences and their tolerance to potential harms are essential to assess.• The decision curve analysis method is an analytical framework where the net clinical benefit is plotted against a range of risk thresholds of having important cancers, helping patients and their physicians to decide between cancer averse (important cancers being detected) and biopsy averse (biopsies avoided) strategies.• The decision curve analysis method showed that the incorporation of clinical risk factors with MRI findings optimizes biopsy outcomes over a range of clinically relevant risk thresholds, compared to other biopsy strategies.

Indexed as

Prostatic NeoplasmsBiopsyHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleProstateProstate-Specific AntigenProstate-Specific AntigenDiagnosisMRI-directed biopsyMultiparametric MRIProstate cancerSystematic biopsy

Identifiers

PMID35103829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.